WAT

Waters Corporation (WAT) 2008 Annual Report Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2008. Waters Corporation is a leading manufacturer of analytical instruments, operating through two primary divisions: the Waters Division (High Performance Liquid Chromatography, Ultra Performance Liquid Chromatography, and Mass Spectrometry) and the TA Division (Thermal Analysis, Rheometry, and Calorimetry). The company serves pharmaceutical, life science, industrial, academic, and government customers globally. Approximately 70% of net sales in 2008 were generated outside the United States.

Key Financial Metrics

Note: Total Debt includes $36.1 million in current notes payable and $500.0 million in long-term debt.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 7% to $1.575 billion, driven by new product introductions (ACQUITY UPLC, Synapt MS), growth in service and consumables, and foreign currency translation benefits (2%). Growth slowed in Q4 2008 due to global economic conditions and a strengthening U.S. dollar.
• Profitability: Operating income rose 12% to $389.8 million. This increase was partially offset by a $7 million litigation provision and a $9 million out-of-period software amortization adjustment.
• Debt Reduction: The company significantly reduced leverage. In October 2008, it prepaid a $150 million term loan and $340 million of revolving debt using cash repatriated from foreign entities. Total debt decreased from approximately $884 million in 2007 to $536 million in 2008.
• Acquisitions: Completed acquisitions of Analytical Products Group (APG) and VTI Corporation in 2008, adding capabilities in environmental testing and sorption analysis.

Guidance, Outlook, and Risks

• Economic Outlook: Management noted a decline in demand in Q4 2008 due to global economic deterioration and reduced capital spending by customers. The company expects the negative impact of foreign currency translation to continue into 2009.
• Capital Allocation: In February 2009, the Board authorized an additional $500 million stock repurchase program. The company expects 2009 capital expenditures to be higher than 2008 due to the construction of a new TA facility in Delaware (estimated cost $33 million).
• Accounting Adjustments: A $16 million tax benefit and a $9 million amortization adjustment were recorded in 2008 to correct prior period errors. Additionally, a $5 million tax provision recorded in Q3 2008 regarding foreign entity reorganization is expected to be reversed in Q1 2009 following new U.S. Treasury regulations.
• Key Risks:
  • Global Economic Conditions: Potential for further deterioration in financial markets affecting customer demand.
  • Foreign Exchange: Approximately 70% of sales are in foreign currencies; a stronger U.S. dollar negatively impacts reported sales.
  • Legal Proceedings: Ongoing patent litigation with Agilent Technologies. A $7 million provision was recorded for a French judgment, with appeals pending in France and Germany.
  • Customer Concentration: While no single customer exceeds 3% of sales, approximately 50% of sales are to the pharmaceutical and biotechnology industries.

Investor Verification Checklist

• Q4 Demand Trends: Verify if the Q4 2008 slowdown in industrial and pharmaceutical spending has persisted into 2009.
• Foreign Currency Impact: Monitor the U.S. dollar's strength against the Euro and Yen, as 70% of sales are international.
• Legal Resolution: Track the status of the Agilent patent litigation appeals in France and Germany to assess potential additional liabilities beyond the $7 million provision.
• Debt Covenants: Confirm continued compliance with the 2007 Credit Agreement leverage and interest coverage ratios, given the reduced debt load.
• Acquisition Integration: Assess the revenue contribution from 2008 acquisitions (APG, VTI) and the pending full acquisition of Thar Instruments.